Gut microbiota affects the hostâs metabolism, and it is suggested that there are differences in gut microbiota composition between patients with type 2 diabetes and healthy individuals. Additionally, dysbiosis may increase the concentration of lipopolysaccharides (LPS), causing metabolic endotoxemia, which induces impaired glucose tolerance. Several studies have reported relationships between metabolic diseases and the gut microbiota; and prebiotics, such as oligosaccharides, are commonly consumed to regulate gut microbiotas in healthy individuals. Galacto-oligosaccharides (GOS) are a major prebiotic, which specifically increase Bifidobacteriaceae abundance. Recent studies have reported that Bifidobacteriaceae improved metabolic endotoxemia or impaired glucose tolerance. However, there are few studies reporting the effects of GOS on patients with type 2 diabetes. In the current study, we compared clinical parameters, faecal gut microbiota, their associated metabolic products and their components such as LPS, and LPS-binding protein (LBP) produced by the host, between patients with diabetes and healthy controls. We then assessed the effects of GOS on glycaemic control, and gut microbiotas and metabolites in patients with type 2 diabetes in a double-blind controlled manner. LBP levels were significantly higher in patients with diabetes than those of healthy subjects, which was consistent with previous reports. The abundance of Bifidobacteriaceae and the diversity of intestinal microbiota were significantly lower in patients with diabetes than in healthy subjects. Interestingly, Bifidobacteriaceae was markedly restored in patients with diabetes after consumption of GOS, whereas LBP and glucose tolerance did not improve during this short-term trial period. In the present study, we demonstrated that GOS can ameliorate dysbiosis in patients with diabetes, and continuous intake of GOS may be a promising method for managing type 2 diabetes.
Cani, P.D. and Delzenne, N.M., 2009. The role of the gut microbiota in energy metabolism and metabolic disease. Current Pharmaceutical Design 15: 1546-1558.
'The role of the gut microbiota in energy metabolism and metabolic disease ' () 15 Current Pharmaceutical Design : 1546 -1558.
Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., Waget, A., Delmée, E., Cousin, B., Sulpice, T., Chamontin, B., Ferrières, J., Tanti, J.F., Gibson, G.R., Casteilla, L., Delzenne, N.M., Alessi, M.C. and Burcelin, R., 2007a. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
'Metabolic endotoxemia initiates obesity and insulin resistance ' () 56 Diabetes : 1761 -1772.
Cani, P.D., Neyrinck, A.M., Fava, F., Knauf, C., Burcelin, R.G., Tuohy, K.M., Gibson, G.R. and Delzenne, N.M., 2007b. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383.
'Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia ' () 50 Diabetologia : 2374 -2383.
Cani, P.D., Osto, M., Geurts, L. and Everard, A., 2012. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3: 279-288.
'Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity ' () 3 Gut Microbes : 279 -288.
Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K., Fierer, N., Peña, A.G., Goodrich, J.K., Gordon, J.I., Huttley, G.A., Kelley, S.T., Knights, D., Koenig, J.E., Ley, R.E., Lozupone, C.A., McDonald, D., Muegge, B.D., Pirrung, M., Reeder, J., Sevinsky, J.R., Turnbaugh, P.J., Walters, W.A., Widmann, J., Yatsunenko, T., Zaneveld, J. and Knight, R., 2010. QIIME allows analysis of high-throughput community sequencing data. Nature Methods 7: 335-336.
'QIIME allows analysis of high-throughput community sequencing data ' () 7 Nature Methods : 335 -336.
Ciubotaru, I., Green, S.J., Kukreja, S. and Barengolts, E., 2015. Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Translational Research: Journal of Laboratory and Clinical Medicine 166: 401-411.
'Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans ' () 166 Translational Research: Journal of Laboratory and Clinical Medicine : 401 -411.
Creely, S.J., McTernan, P.G., Kusminski, C.M., Fisher, F.M., Da Silva, N.F., Khanolkar, M., Evans, M., Harte, A.L. and Kumar, S., 2007. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. American Journal of Physiology â Endocrinology and Metabolism 292: E740-E747.
'Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes ' () 292 American Journal of Physiology â Endocrinology and Metabolism : E740 -E747.
Dehghan, P., Pourghassem Gargari, B. and Asghari Jafar-abadi, M., 2014. Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 30: 418-423.
'Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial ' () 30 Nutrition : 418 -423.
Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N. and Knight, R., 2010. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proceedings of the National Academy of Science of the USA 107: 11971-11975.
'Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns ' () 107 Proceedings of the National Academy of Science of the USA : 11971 -11975.
Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Krogh Pedersen, H., Arumugam, M., Kristiansen, K., Voigt, A.Y., Vestergaard, H., Hercog, R., Igor Costea, P., Kultima, J.R., Li, J., Jørgensen, T., Levenez, F., Dore, J., MetaHIT Consortium, Nielsen, H.B., Brunak, S., Raes, J., Hansen, T., Wang, J., Ehrlich, S.D., Bork, P. and Pedersen, O., 2015. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528: 262-266.
'Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota ' () 528 Nature : 262 -266.
Frost, G., Sleeth, M.L., Sahuri-Arisoylu, M., Lizarbe, B., Cerdan, S., Brody, L., Anastasovska, J., Ghourab, S., Hankir. M., Zhang, S., Carling, D., Swann, J.R., Gibson, G., Viardot, A., Morrison, D., Louise Thomas, E. and Bell, J.D., 2014. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nature Communications 5: 3611.
'The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism ' () 5 Nature Communications : 3611.
Furet, J.P., Kong, L.C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.L., Mariat, D., Corthier, G., Doré, J., Henegar, C., Rizkalla, S. and Clément, K., 2010. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59: 3049-3057.
'Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers ' () 59 Diabetes : 3049 -3057.
Goodrich, J.K., Waters, J.L., Poole, A.C., Sutter, J.L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J.T., Spector, T.D., Clark, A.G. and Ley, R.E., 2014. Human genetics shape the gut microbiome. Cell 159: 789-799.
'Human genetics shape the gut microbiome ' () 159 Cell : 789 -799.
Griffiths, E.A., Duffy, L.C., Schanbacher, F.L., Qiao, H., Dryja, D., Leavens, A., Rossman, J., Rich, G., Dirienzo, D. and Ogra, P.L., 2004. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Digestive Diseases and Sciences 49: 579-589.
'In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice ' () 49 Digestive Diseases and Sciences : 579 -589.
Kaneko, K., Watanabe, Y., Kimura, K., Matsumoto, K., Mizobuchi, T. and Onoue, M., 2014. Development of hypoallergenic galacto-oligosaccharides on the basis of allergen analysis. Bioscience, Biotechnology, and Biochemistry 78: 100-108.
'Development of hypoallergenic galacto-oligosaccharides on the basis of allergen analysis ' () 78 Bioscience, Biotechnology, and Biochemistry : 100 -108.
Karlsson, F.H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C.J., Fagerberg, B., Nielsen, J. and Bäckhed, F., 2013. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498: 99-103.
'Gut metagenome in European women with normal, impaired and diabetic glucose control ' () 498 Nature : 99 -103.
Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., Terasawa, K., Kashihara, D., Hirano, K., Tani, T., Takahashi, T., Miyauchi, S., Shioi, G., Inoue, H. and Tsujimoto, G., 2013. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nature Communications 4: 1829.
'The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43 ' () 4 Nature Communications : 1829.
Le, T.K., Hosaka, T., Le, T.T., Nguyen, T.G., Tran, Q.B., Le, T.H. and Pham, X.D., 2014. Oral administration of Bifidobacterium spp. improves insulin resistance, induces adiponectin, and prevents inflammatory adipokine expressions. Biomedical Research 35: 303-310.
'Oral administration of Bifidobacterium spp ' () 35 Biomedical Research : 303 -310.
Matsuki, T., Watanabe, K., Fujimoto, J., Kado, Y., Takada, T., Matsumoto, K. and Tanaka, R., 2004. Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Applied and Environmental Microbiology 70: 167-173.
'Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria ' () 70 Applied and Environmental Microbiology : 167 -173.
Matsumoto, K., Takada, T., Shimizu, K., Moriyama, K., Kawakami, K., Hirano, K., Kajimoto, O. and Nomoto, K., 2010. Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools. Journal of Bioscience and Bioengineering 110: 547-552.
'Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools ' () 110 Journal of Bioscience and Bioengineering : 547 -552.
Moreno-Navarrete, J.M., Ortega, F., Serino, M., Luche, E., Waget, A., Pardo, G., Salvador, J., Ricart, W., Frühbeck, G., Burcelin, R. and Fernández-Real, J.M., 2012. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. International Journal of Obesity 36: 1442-1449.
'Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance ' () 36 International Journal of Obesity : 1442 -1449.
Nakayama, J., Watanabe, K., Jiang, J., Matsuda, K., Chao, S.H., Haryono, P., La-Ongkham, O., Sarwoko, M.A., Sujaya, I.N., Zhao, L., Chen, K.T., Chen, Y.P., Chiu, H.H., Hidaka, T., Huang, N.X., Kiyohara, C., Kurakawa, T., Sakamoto, K., Tashiro, K., Tsuji, H., Chen, M.J., Leelavatcharamas, V., Liao, C.C., Nitisinprasert, S., Rahayu, E.S., Ren, F.Z., Tsai, Y.C. and Lee, Y.K., 2015. Diversity in gut bacterial community of school-age children in Asia. Scientific Reports 5: 8397.
'Diversity in gut bacterial community of school-age children in Asia ' () 5 Scientific Reports : 8397.
Newburg, D.S., Ko, J.S., Leone, S. and Nanthakumar, N.N., 2016. Human milk oligosaccharides and synthetic galactosyloligosaccharides contain 3â-, 4â-, and 6â-galactosyllactose and attenuate inflammation in human T84, NCM-460, and H4 cells and intestinal tissue ex vivo. Journal of Nutrition 146: 358-367.
'Human milk oligosaccharides and synthetic galactosyloligosaccharides contain 3â-, 4â-, and 6â-galactosyllactose and attenuate inflammation in human T84, NCM-460, and H4 cells and intestinal tissue ex vivo ' () 146 Journal of Nutrition : 358 -367.
Peterson, C.T., Sharma, V., Elmén, L. and Peterson, S.N., 2015. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clinical and Experimental Immunology 179: 363-377.
'Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota ' () 179 Clinical and Experimental Immunology : 363 -377.
Pourghassem Gargari, B., Dehghan, P., Aliasgharzadeh, A. and Asghari Jafar-Abadi, M., 2013. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes and Metabolism Journal 37: 140-148.
'Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes ' () 37 Diabetes and Metabolism Journal : 140 -148.
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., Peng, Y., Zhang, D., Jie, Z., Wu, W., Qin, Y., Xue, W., Li, J., Han, L., Lu, D., Wu, P., Dai, Y., Sun, X., Li, Z., Tang, A., Zhong, S., Li, X., Chen, W., Xu, R., Wang, M., Feng, Q., Gong, M., Yu, J., Zhang, Y., Zhang, M., Hansen, T., Sanchez, G., Raes, J., Falony, G., Okuda, S., Almeida, M., LeChatelier, E., Renault, P., Pons, N., Batto, J.M., Zhang, Z., Chen, H., Yang, R., Zheng, W., Li, S., Yang, H., Wang, J., Ehrlich, S.D., Nielsen, R., Pedersen, O., Kristiansen, K. and Wang, J., 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490: 55-60.
'A metagenome-wide association study of gut microbiota in type 2 diabetes ' () 490 Nature : 55 -60.
Samuel, B.S., Shaito, A., Motoike, T., Rey, F.E., Backhed, F., Manchester, J.K., Hammer, R.E., Williams, S.C., Crowley, J., Yanagisawa, M. and Gordon, J.I., 2008. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the National Academy of Sciences of the USA 105: 16767-16772.
'Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41 ' () 105 Proceedings of the National Academy of Sciences of the USA : 16767 -16772.
Sangwan, V., Tomar, S.K., Ali, B., Singh, R.R. and Singh, A.K., 2015. Hypoglycaemic effect of galactooligosaccharides in alloxan-induced diabetic rats. Journal of Dairy Research 82: 70-77.
'Hypoglycaemic effect of galactooligosaccharides in alloxan-induced diabetic rats ' () 82 Journal of Dairy Research : 70 -77.
Sato, J., Kanazawa, A., Ikeda, F., Yoshihara, T., Goto, H., Abe, H., Komiya, K., Kawaguchi, M., Shimizu, T., Ogihara, T., Tamura, Y., Sakurai, Y., Yamamoto, R., Mita, T., Fujitani, Y., Fukuda, H., Nomoto, K., Takahashi, T., Asahara, T., Hirose, T., Nagata, S., Yamashiro, Y. and Watada, H., 2014. Gut dysbiosis and detection of âlive gut bacteriaâ in blood of Japanese patients with type 2 diabetes. Diabetes Care 37: 2343-2350.
'Gut dysbiosis and detection of âlive gut bacteriaâ in blood of Japanese patients with type 2 diabetes ' () 37 Diabetes Care : 2343 -2350.
Schnorr, S.L., Candela, M., Rampelli, S., Centanni, M., Consolandi, C., Basaglia, G., Turroni, S., Biagi, E., Peano, C., Severgnini, M., Fiori, J., Gotti, R., De Bellis, G., Luiselli, D., Brigidi, P., Mabulla, A., Marlowe, F., Henry, A.G. and Crittenden, A.N., 2014. Gut microbiome of the Hadza hunter-gatherers. Nature Communications 5: 3654.
'Gut microbiome of the Hadza hunter-gatherers ' () 5 Nature Communications : 3654.
Sumiyoshi, W., Urashima, T., Nakamura, T., Arai, I., Nagasawa, T., Saito, T., Tsumura, N., Wang, B., Brand-Miller, J., Watanabe, Y. and Kimura, K., 2004. Galactosyllactoses in the milk of Japanese women: changes in concentration during the course of lactation. Journal of Applied Glycoscience 51: 341-344.
'Galactosyllactoses in the milk of Japanese women: changes in concentration during the course of lactation ' () 51 Journal of Applied Glycoscience : 341 -344.
Tilves, C.M., Zmuda, J.M., Kuipers, A.L., Nestlerode, C.S., Evans, R.W., Bunker, C.H., Patrick, A.L. and Miljkovic, I., 2016. Association of lipopolysaccharide-binding protein with aging-related adiposity change and prediabetes among African ancestry men. Diabetes Care 39: 385-391.
'Association of lipopolysaccharide-binding protein with aging-related adiposity change and prediabetes among African ancestry men ' () 39 Diabetes Care : 385 -391.
Wang, Z., Xiao, G., Yao, Y., Guo, S., Lu, K. and Sheng, Z., 2006. The role of bifidobacteria in gut barrier function after thermal injury in rats. Journal of Trauma and Acute Care Surgery 61: 650-657.
'The role of bifidobacteria in gut barrier function after thermal injury in rats ' () 61 Journal of Trauma and Acute Care Surgery : 650 -657.
Wu, X., Ma, C., Han, L., Nawaz, M., Gao, F., Zhang, X., Yu, P., Zhao, C., Li, L., Zhou, A., Wang, J., Moore, J.E., Millar, B.C. and Xu, J., 2010. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Current Microbiology 61: 69-78.
'Molecular characterisation of the faecal microbiota in patients with type II diabetes ' () 61 Current Microbiology : 69 -78.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 0 | 0 | 0 |
| å ¨ææµè§æ¬¡æ° | 767 | 358 | 49 |
| PDFä¸è½½æ¬¡æ° | 789 | 340 | 28 |
Gut microbiota affects the hostâs metabolism, and it is suggested that there are differences in gut microbiota composition between patients with type 2 diabetes and healthy individuals. Additionally, dysbiosis may increase the concentration of lipopolysaccharides (LPS), causing metabolic endotoxemia, which induces impaired glucose tolerance. Several studies have reported relationships between metabolic diseases and the gut microbiota; and prebiotics, such as oligosaccharides, are commonly consumed to regulate gut microbiotas in healthy individuals. Galacto-oligosaccharides (GOS) are a major prebiotic, which specifically increase Bifidobacteriaceae abundance. Recent studies have reported that Bifidobacteriaceae improved metabolic endotoxemia or impaired glucose tolerance. However, there are few studies reporting the effects of GOS on patients with type 2 diabetes. In the current study, we compared clinical parameters, faecal gut microbiota, their associated metabolic products and their components such as LPS, and LPS-binding protein (LBP) produced by the host, between patients with diabetes and healthy controls. We then assessed the effects of GOS on glycaemic control, and gut microbiotas and metabolites in patients with type 2 diabetes in a double-blind controlled manner. LBP levels were significantly higher in patients with diabetes than those of healthy subjects, which was consistent with previous reports. The abundance of Bifidobacteriaceae and the diversity of intestinal microbiota were significantly lower in patients with diabetes than in healthy subjects. Interestingly, Bifidobacteriaceae was markedly restored in patients with diabetes after consumption of GOS, whereas LBP and glucose tolerance did not improve during this short-term trial period. In the present study, we demonstrated that GOS can ameliorate dysbiosis in patients with diabetes, and continuous intake of GOS may be a promising method for managing type 2 diabetes.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 0 | 0 | 0 |
| å ¨ææµè§æ¬¡æ° | 767 | 358 | 49 |
| PDFä¸è½½æ¬¡æ° | 789 | 340 | 28 |